Supplementary appendix

Prognostic implication of post-percutaneous coronary intervention neutrophil-to-lymphocyte ratio on infarct size and clinical outcomes in patients with acute myocardial infarction

David Hong, MD¹⁺, Ki Hong Choi, MD¹⁺, Young Bin Song, MD, PhD^{1*}, Joo Myung Lee, MD, MPH, PhD¹, Taek Kyu Park, MD, PhD¹, Jeong Hoon Yang, MD, PhD^{1,2}, Joo-Yong Hahn, MD, PhD¹, Jin-Ho Choi, MD, PhD^{1,3}, Seung-Hyuk Choi, MD, PhD¹, Sung Mok Kim, MD, PhD⁴, Yeonhyeon Choe, MD, PhD⁴, Eun Kyoung Kim, MD, PhD⁵, Sung A Chang, MD, PhD⁵, Sang-Chol Lee, MD, PhD⁵, Jae K. Oh, MD, PhD^{5,6}, Hyeon-Cheol Gwon, MD, PhD¹

Table of contents

(1) Supplementary Tables

(2) Supplementary Figures and Figure legends

(1) Supplementary Tables

Supplementary Table 1. Standardized differences of variables used in IPW adjustment to adjust baseline differences between the


NLR≥3.88 and NLR<3.88 group

	Standardized differences, %	
	Unadjusted	IPW-adjusted
Age	24.17	7.27
Sex	-4.33	-7.20
Body mass index, kg/m ²	-27.18	1.67
Hypertension	9.28	6.92
Diabetes	19.72	2.67
Dyslipidemia	-13.03	2.96
History of myocardial infarction	26.64	4.13
History of percutaneous coronary intervention	29.21	4.93
History of cerebrovascular accident	4.25	-0.13
STEMI	51.17	5.41
Hemoglobin, g/dL	-21.37	-4.13
Platelet, $10^3/uL$	12.37	0.84
Anterior infarction	19.91	8.50
Multi-vessel disease	17.14	1.53
Pre-PCI TIMI flow ≤1	24.02	-1.26
Post-PCI TIMI flow 3	10.58	-1.07
Thrombus aspiration	15.44	1.19
Number of implanted stent	-2.46	-0.63
Stent diameter <3 mm	23.55	-0.94
Aspirin	0	0
P2Y12 Inhibitor	2.92	2.46
Beta-blocker	-4.31	5.32
ACE inhibitor or ARB	-16.61	-1.95

Statin	-13.54	-0.44		
Abbreviations: ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, IPW inverse probability weighting, NLR neutrophil to				
lymphocyte ratio, PCI percutaneous coronary intervention, STEMI S	ST-segment elevation myocardia	l infarction, TIMI thrombolysis in		
myocardial infarction.				

(2) Supplementary Figures and Figure legends


Supplementary Figure 1. Late gadolinium enhancement and T2-weighted images of an acute myocardial infarction patient.



Representative cardiac magnetic resonance images of an acute myocardial infarction patient after revascularization. Areas shown in each figure are (A) area at risk and (B) infarct size and microvascular obstruction.

Abbreviations: AAR area at risk, IS infarct size, MVO microvascular obstruction


Supplementary Figure 2. ROC curves between pre- and post-leukocyte count and large size infarction (≥20%)



ROC curve analyses were presented to compare the discriminative accuracy of WBC and NLR before and after PCI to predict large size infarction.


Abbreviations: *NLR* neutrophil to lymphocyte ratio, *PCI* percutaneous coronary intervention, *ROC* receiver-operator-characteristic, *WBC* white blood cell counts

Supplementary Figure 3. Cumulative incidence of clinical outcomes at 2-year



Kaplan-Meier curves are presented to compare the cumulative incidence of (A) all cause death, (B) myocardial infarction, and (C) any revascularization according to NLR 3.88.


Abbreviations: NLR neutrophil to lymphocyte ratio




Supplementary Figure 4. Cardiac MRI findings in STEMI patients

Box-whisker plots are presented to compare the extent of (A) infarct size, (B) area at risk, (C) microvascular obstruction, and (D) myocardial salvage index in STEMI patients according to NLR 3.88.

Abbreviations: LV left ventricle, MRI magnetic resonance imaging, NLR neutrophil to lymphocyte ratio, STEMI ST-segment elevation myocardial infarction





Kaplan-Meier curves are presented to compare the cumulative incidence of MACE in STEMI patients according to NLR 3.88

Abbreviations: MACE major adverse cardiac event, NLR neutrophil to lymphocyte ratio, STEMI ST-segment elevation myocardial infarction